Valeant Pharmaceuticals, parent company of Bausch & Lomb and other operations, has reported an overall sales increase of 9 percent to $2.37 billion for the first quarter ended March 31, as compared to the restated turnover for the year-ago period, but the increase was mainly due to new acquisitions. In particular, revenues from contact lenses rose by 9 percent to $52.1 million, but those of the group's ophthalmology RX business unit fell by 30 percent to $90.7 million. On an organic basis, total revenues fell by $289 million, leading the group to cut down its forecast for the full year. They generated a net loss of $373.7 million and an adjusted net profit of $442.6 million for the quarter, down from adjusted and restated net earnings of $704.2 million, disappointing investors. Valeant is under investigation for its accounting and business practices.